These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 2547748

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In vitro activity of YTR 830.
    Jacobs MR, Aronoff SC, Appelbaum PC, Yamabe S.
    J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029
    [Abstract] [Full Text] [Related]

  • 4. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.
    Aronoff SC, Jacobs MR, Johenning S, Yamabe S.
    Antimicrob Agents Chemother; 1984 Oct; 26(4):580-2. PubMed ID: 6097169
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam.
    Moosdeen F, Williams JD, Yamabe S.
    Antimicrob Agents Chemother; 1988 Jun; 32(6):925-7. PubMed ID: 2843088
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
    Jacobs MR, Aronoff SC, Johenning S, Shlaes DM, Yamabe S.
    Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.
    Appelbaum PC, Jacobs MR, Spangler SK, Yamabe S.
    Antimicrob Agents Chemother; 1986 Nov; 30(5):789-91. PubMed ID: 3026241
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of beta-lactamase inhibitors on beta-lactamases from anaerobic bacteria.
    Hedberg M, Lindqvist L, Tunér K, Nord CE.
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1100-4. PubMed ID: 1338315
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.